Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A triple tumor study of MAGE-A10 SPEAR T-cell therapy in patients with inoperable or metastatic urothelial cancer, melanoma, or squamous cell carcinoma of the head and neck

Next Previous
X
Search
Trial Profile

A triple tumor study of MAGE-A10 SPEAR T-cell therapy in patients with inoperable or metastatic urothelial cancer, melanoma, or squamous cell carcinoma of the head and neck

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MAGE A-10 TCR-transduced lymphocytes (Primary)
  • Indications Bladder cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Adaptimmune

    • Most Recent Events

    • 01 Aug 2019 According to an Adaptimmune Media release, enrollment in this trial is expected to be closed by end of 2019.
    • 27 Feb 2019 According to an Adaptimmune media release, initial safety testing has been completed in this trial. In 4Q 2018 the trial was expanded for doses up to 10 billion cells with no pre-determined stagger between patients.
    • 20 Oct 2018 According to an Adaptimmune media release,safety data from Cohorts 1 and 2 of this trial were presented at 2018 ESMO Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top